Medserv announced earnings results for the year ended December 31, 2016. For the year, the company announced revenue of EUR 32.8 million compared to EUR 42.7 million a year ago. EBITDA was EUR 5.0 million compared to EUR 10.3 million a year ago. Operating profit (before amort. and except.) was EUR 1.6 million compared to EUR 7.6 million a year ago. Operating profit was EUR 0.5 million compared to EUR 7.3 million a year ago. Loss before tax (norm) was EUR 1.3 million compared to profit of EUR 6.1 million a year ago. Loss before tax (FRS 3) was EUR 2.3 million compared to profit of EUR 5.8 million a year ago. Loss after tax (norm) was EUR 1.3 million compared to profit of EUR 4.8 million a year ago. Profit after tax (FRS 3) was EUR 3.1 million compared to profit of EUR 4.5 million a year ago. LPS - normalised and fully diluted was EUR 2.1 compared to EPS of 9.7 a year ago. EPS - (IFRS) was EUR 6.2 compared to EPS of 8.9 a year ago. Operating cash flow was EUR 6.0 million compared to EUR 10.4 million a year ago. Capex was EUR 2.4 million compared to EUR 1.7 million a year ago. Net cash flow was EUR 21.8 million compared to EUR 0.3 million a year ago. Closing net debt was EUR 47.8 million compared to EUR 25.2 million a year ago.

For 2018, the company expects revenue of EUR 42.3 million, EBITDA of EUR 12.4 million, operating profit of EUR 7.0 million, profit before tax (norm) of EUR 5.9 million, profit before tax (FRS 3) of EUR 4.2 million, profit after tax (norm) of EUR 5.3 million, profit after tax (FRS 3) of EUR 3.7 million, EPS - normalised of EUR 9.6 and operating cash flow of EUR 6.8 million.

For 2017, the company expects revenue of EUR 35.2 million compared to previous guidance of EUR 49.2 million, EBITDA of EUR 7.0 million compared to previous guidance of EUR 14.3 million, EBITDA of EUR 3.4 million compared to previous guidance of EUR 9.4 million, EBIT reported of EUR 1.7 million compared to previous guidance of EUR 7.7 million, Underlying PBT of EUR 0.5 million compared to previous guidance of EUR 6.6 million, EPS - underlying continuing of EUR 0.6 million compared to previous guidance of EUR 11.0 million and net debt of EUR 45.1 million against EUR 40.6 million.